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Abstract
Background: The critical event in heart formation is commitment of mesodermal cells to a cardiomyogenic fate, and cardiac
fate determination is regulated by a series of cytokines. Bone morphogenetic proteins (BMPs) and fibroblast growth factors
have been shown to be involved in this process, however additional factors needs to be identified for the fate
determination, especially at the early stage of cardiomyogenic development.
Methodology/Principal Findings: Global gene expression analysis using a series of human cells with a cardiomyogenic
potential suggested Gremlin (Grem1) is a candidate gene responsible for in vitro cardiomyogenic differentiation. Grem1, a
known BMP antagonist, enhanced DMSO-induced cardiomyogenesis of P19CL6 embryonal carcinoma cells (CL6 cells) 10–35
fold in an area of beating differentiated cardiomyocytes. The Grem1 action was most effective at the early differentiation
stage when CL6 cells were destined to cardiomyogenesis, and was mediated through inhibition of BMP2. Furthermore,
BMP2 inhibited Wnt/b-catenin signaling that promoted CL6 cardiomyogenesis.
Conclusions/Significance: Grem1 enhances the determined path to cardiomyogenesis in a stage-specific manner, and
inhibition of the BMP signaling pathway is involved in initial determination of Grem1-promoted cardiomyogenesis. Our
results shed new light on renewal of the cardiovascular system using Grem1 in human.
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Introduction
The critical event in heart formation is commitment of
mesodermal cells to a cardiomyogenic fate and their migration into
anterolateral regions of the embryo during late gastrulation. In this
process, morphogenic movements and cardiac fate determination
are regulated by cytokines such as bone morphogenetic proteins
(BMPs) [1–3], and fibroblast growth factors (FGFs) [4–7]. These
secreted proteins from neighboring endoderm, ectoderm, and the
mesoderm itself, play important roles in induction of cardiac
transcription factors [8] and differentiation of cardiomyocytes in
amphibians [9] and avians [4]. Cardiomyogenic signals, such as
BMPs and FGFs, indeed activate expression of cardiac specific
transcriptional factors (Csx/Nkx2.5, Gata4, Mef2c), and these
transcriptional factors activate expression of circulating hormones
(atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP)),
and cardiac specific proteins (myosin heavy chain (MyHC), myosin
light chain (MyLC)). Wnt family proteins, cysteine-rich, and secreted
glycoproteins, have also been implicated in embryonic development
[10,11], and cardiomyogenesis [12,13]. In Drosophila,‘ wingless’, a
homologue of vertebrate Wnt is involved in expression of ‘tinman’, a
Drosophila homologue of Csx/Nkx2.5, through ‘armadillo’, a Drosophila
ortholog of b-catenin, and drives heart development [14]. In
vertebrates, however, Wnt1/3a, which activates the canonical Wnt/
b-catenin signaling pathway leading to stabilization of b-catenin as a
downstream molecule through inactivation of glycogen synthase
kinase-3b, inhibits cardiomyocytic differentiation from cardiac
mesoderm [15–18]. Wnt11 promotes cardiac differentiation via
the non-canonical pathway in Xenopus [12] and murine embryonic
cell lines [19]. The secretion of Wnt inhibitors such as ‘Cerberus’,
‘Dickkopf’ and ‘Crescent’ by the anterior endoderm prevents Wnt3a
secreted by the neural tube from inhibiting heart formation [15–17].
In this study, we performed GeneChip analysis to identify
multiple extracellular determinants, such as cytokines, cell
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myogenic differentiation, and evaluated the statistical significance
of differential gene expression by NIA array analysis (http://lgsun.
grc.nia.nih.gov/ANOVA/) [20], a web-based tool for microarray
data analysis. We found that Grem1 enhances the determined
path to cardiomyogenesis in a stage-specific manner, and that
inhibition of the BMP signaling pathway is, at least in part,
involved in initial determination of Grem1-promoted cardiomyo-
genesis.
Results
GeneChip and statistical analysis
To identify cytokines and transcription factors responsible for
cardiomyogenic differentiation, 69 human cells were analyzed,
depending on gene expression levels, by GeneSpringGX software,
and clustered into 30 groups (Fig. 1A, Table 1). Among the 30
groups, 21 groups included cells with a cardiomyogenic potential
(Fig. 1B: red numbers). To identify genes specific for these groups,
hierarchical clustering was employed, using the average distance
method. Genes with the lowest average expression E(G1) within
the cluster that can differentiate into cardiomyocytes and genes
with the highest average expression E(G2) outside the cluster were
identified, as previously described [20–22]. Genes which have
E(G1).E(G2) were estimated, using the False Discovery Rate
(FDR,0.05). Grem1 was nominated as a cluster-specific cardio-
myocyte-promoting gene in cells that could differentiate into
cardiomyocytes following NIA array analysis (Fig. 1B). The gene
expression profile reported in this paper has been deposited in the
Gene Expression Omnibus (GEO) database (http://www.ncbi.
nlm.nih.gov/geo: accession no. GSE8481, GSM41342-
GSM41344, and GSM201137- GSM201145).
Cardiomyogenic differentiation of CL6 cells with Grem1
and DMSO
To investigate cardiomyogenic activity of Grem1, P19CL6
embryonal carcinoma cells (CL6 cells) were used for assessment of
in vitro cardiomyogenic differentiation, since CL6 cells are
reproducibly and stably induced into beating cardiomyocytes by
DMSO (Fig. 2Aa) [23]. CL6 cells did not differentiate following
exposure to Grem1 alone at concentrations of 63 or 125 ng/ml for
14 days (Fig. 2B). However, Grem1 dramatically promotes
DMSO-induced cardiomyogenic differentiation at a concentration
of 63 and 125 ng/ml; Grem1 (125 ng/ml) especially increased
DMSO-induced cardiomyogenic differentiation of CL6 cells as
assessed by beating area (Fig. 2Ab and B) (Movie S1 and S2,
http://1954.jukuin.keio.ac.jp/umezawa/kami/index.html).
RT-PCR of differentiated or undifferentiated CL6 cells
To investigate gene expression as well as morphological
analysis, i.e. beating, during cardiomyogenic differentiation, RT-
PCR analysis was performed to detect expression of cardiomyo-
cyte-specific/associate transcription factors, and structural genes
(Fig. 2C). Genes encoding Csx/Nkx2.5, Gata4, Hand2, Mef2c, ANP,
BNP, MyLC-2a, MyLC-2v, and b-MyHC were up-regulated during
cardiomyogenic differentiation of CL6 cells treated with Grem1
and DMSO (Fig. 2C: lanes 6, 7 versus lane 3). Triplicate
independent experiments confirmed the concentration-dependent
Grem1 action on cardiomyogenic differentiation. The cardiomy-
ocyte-specific genes (Csx/Nkx2.5, Gata4, MyLC-2a, MyLC-2v)
expression level of CL6 cells treated with DMSO and Grem1
(63 and 125 ng/ml) were also the same as or higher than that
of DMSO-induced CL6 cells by semi-quantitative RT-PCR
(Figure S1).
Immunocytochemistry of differentiated or
undifferentiated CL6 cells
To examine CL6 cells for expression of cardiomyocytic protein,
immunocytochemical analysis was performed. CL6 treated with
Grem1 (125 ng/ml) and DMSO exhibited clear striation with
immunostain using anti-cTnT or anti-a-actinin (Fig. 2Da and b).
The MF20- and cTnT-positive cells after exposure to Grem1 and
DMSO formed clusters (Fig. 2Ea), compared with the cells after
exposure to DMSO alone (Fig. 2Eb). CL6 cells treated with
Grem1 alone were negative for MF20 and cTnT, but became
positive for both markers following exposure to Grem1 (63 and
125 ng/ml) and DMSO (Fig. 2F). The beating area (Fig. 2B)
showed a tendency similar to the MF20- and cTnT-positive area
(Fig. 2F), thus there were positive correlations between them.
Figure 1. Hierarchical clustering analysis on cultured human
cells. (A) Hierarchical clustering analyzed by GeneSpring. Based on
gene expression pattern, 69 human cells were clustered into 30 sub-
groups. The raw data from the GeneChip analysis are available at the
GEO database with accession number GSE8481, GSM41342- GSM41344,
and GSM201137- GSM201145. (B) Hierarchical clustering analysis was
performed by NIA array (http://lgsun.grc.nia.nih.gov/ANOVA/), using
averaged values of 30 sub-groups. Among the 30 groups, 21 groups
included cells with a cardiomyogenic potential. To identify genes
specific for these groups, hierarchical clustering was employed. Grem1
was nominated as a cluster-specific cardiomyocyte-promoting gene in
cells that could differentiate into cardiomyocytes.
doi:10.1371/journal.pone.0002407.g001
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Group Title Description GSM
1 Normal epithelial cell,primary NHEK-Neo1 Normal epidermal keratinocyte, neonate, primary GSM210361
NHBE-1 Normal bronchial epithelial cell, primary GSM210362
2 Pulmonary epithelial cell line A549 Pulmonary epithelial cell line GSM210363
BEAS-2B control (6hr) Bronchial epithelial cell line GSM210364
3 Lymphocyte RPMI8226control (6hr) B cell line GSM210365
Raji-1 B cell line GSM210366
NK92 NK cell line GSM210367
4 Myelomonocytic leukemia U937c U937 control GSM210368
U937h U937+HRF GSM210369
U937ha U937+HRF+antibody GSM210370
U937a U937+antibody GSM210371
5 Embryonal carcinoma, cancer NCR-G3 Embryonal carcinoma, NCR-G3, non-adherent GSM201141
NCR-G2NAd Embryonal carcinoma, NCR-G2, non-adherent GSM210373
NCR-G4Ad Embryonal carcinoma, NCR-G4, adherent GSM201142
NCR-G3Ad Embryonal carcinoma, NCR-G3, adherent GSM210375
6 ES cell H1_P43 Undifferentiated hES GSM41342
H1-P46 Undifferentiated hES GSM41343
H1-P41 Undifferentiated hES GSM41344
7 Embryonal carcinoma, cancer NCR-G2Ad Embryonal carcinoma, NCR-G2, adherent GSM201140
NCR-G1 Embryonal carcinoma, NCR-G3, non-adherent GSM201139
8 Ewing, cancer NCR-EW2 Ewing, cancer GSM210378
NCR-EW3 Ewing, ETV4, cancer GSM210379
9 Ewing, cancer GST6 Ewing, POU5F1, cancer GSM201137
GST6-extra Ewing, POU5F1, cancer GSM210381
10 Ewing, cancer GST6-5az Ewing, POU5F1, 5azaC, cancer GSM201138
GST6-5az-extra Ewing, POU5F1, 5azaC, cancer GSM210383
11 Bone marrow cell, primary H4-1 Bone marrow cell, primary GSM201143
UBT5 Bmi-1, hTERT, bone marrow cell GSM210385
UBET7 Bmi-1, E6, hTERT, bone marrow cell GSM210386
12 Ligament-derived cells #10 Ligament, primary GSM210387
Marrow stromal cells H10-2Vec Vector, bone marrow cell GSM210388
H10-2TERT hTERT, bone marrow cell GSM210389
H10-2Bmi1 Bmi-1, bone marrow cell GSM210390
13 Placenta, primary PL90 Placenta, primary GSM210391
14 De-differentiated chondrocyte TdHC1 E6, E7, hTERT, de-differentiated chondrocyte GSM210392
15 Neural differentiated marrow stromal cell UET13 Neural differentiation E7, hTERT, neural differentiation, bone marrow cell GSM210393
16 Neural differentiated marrow stromal cell UET13 Neural differentiation1 E7, hTERT, neural differentiation, bone marrow cell GSM210394
UET13 Neural differentiation4 E7, hTERT, neural differentiation, bone marrow cell GSM210395
UET13 Neural differentiation5 E7, hTERT, neural differentiation, bone marrow cell GSM210396
17 Cord blood-derived cells UET13 E7, hTERT, bone marrow cell GSM210397
UCB408 Cord blood, primary GSM210398
UCB408E6E7-31 E6, E7, umbilical cord blood GSM210399
Adipocyte cell, primary HAdPC1(5/21) HAdpc1E6E7TERT28 GSM210400
18 Marrow mesenchymal cell, primary UEET12 E6, E7, hTERT, bone marrow cell GSM210401
UEE16 E6, E7, bone marrow cell GSM210402
EPC hTERT+1 E6, E7, hTERT, endometrial cell GSM201144
19 Cord blood, primary UCB302 Cord blood, primary GSM210382
UCB302-D7 Cord blood, primary GSM210405
UCB302TERT hTERT, cord blood GSM210406
UET9 E7, hTERT, bone marrow cell GSM210407
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(days 1–3) of CL6 differentiation
To determine if Grem1 (125 ng/ml) functions during the early
or the late stage of differentiation, CL6 cells were treated with
Grem1 for different time periods (Fig. 3A). Grem1 and DMSO
were most effective on CL6 differentiation at 1–3 days (Fig. 3B, C)
as assessed by percentages of MF20-positive area and beating area.
Since Grem1 inhibits BMPs through direct binding [24], we
hypothesized that BMP signaling is inhibitory to CL6 cardiomyo-
genesis during days 1–3. To confirm this hypothesis, RT-PCR
analysis was performed to determine expression of the early
mesodermal marker (BrachyuryT and Tbx6), cardiomyocyte-specific
transcription factors (Csx/Nkx2.5), structural genes (b-MyHC), and
Gapdh (Fig. 4A). DMSO induced the BrachyuryT and Tbx6 genes,
and their expressions peaked at 3 days and then decreased; BMP2
down-regulated expression of these genes at 3–7 days. The Csx/
Nkx2.5 and b-MyHC genes started to be expressed at days 3 and 5,
respectively, and their expression increased up to 14 days, at which
time the timeframe analysis was terminated. BMP2 clearly
inhibited expression of the Csx/Nkx2.5 and b-MyHC genes
(Fig. 4A, lanes 1–7 versus lanes 8–14).
To examine cardiomyogenic differentiation, immunocytochem-
ical analysis was performed on CL6 cells treated with the inducers.
CL6 cells treated with DMSO and BMP2 for the first 3 days were
negative for sarcomeric myosin (MF20) at 14 days, but became
positive for sarcomeric myosin, following exposure to DMSO
alone during days 1–3 (Fig. 4B). To determine if DMSO induces
BMP production in CL6 cells, expression levels of Bmp2 and Bmp4
were determined by quantitative real-time RT-PCR analysis
(Fig. 4C). DMSO clearly induced the Bmp2 and Bmp4 genes, and
DMSO-induction was inhibited by BMP2 protein. The expression
level of Bmp2 was highest during days 7–10 (Fig. 4C: Bmp2)i n
DMSO-induced CL6 cells, and that of Bmp4 was highest during
days 5–7 (Fig. 4C: Bmp4).
To investigate BMP signaling on cardiomyogenic differentiation,
we used the Id1 promoter-Lux plasmid that includes the luciferase
gene driven by the Id1 promoter, known as a BMP target promoter
(Fig. 4D). DMSO increased BMP signaling activity that peaked at 5
days (Fig. 4D, open square). BMP2 protein increased BMP signaling
activity at 3 days (Fig. 4D, closed square), but lost BMP signaling
activity at 5 days and later, implying that this loss of BMP signaling
leads to lack of cardiomyogenic induction.
Since Wnt/b-catenin signaling is involved in CL6 cardiomyo-
genesis [23,25], we hypothesized that the BMP effect on CL6
cardiomyogenesis is mediated through Wnt/b-catenin signaling.
Expression of Wnt3a, an activator of canonical Wnt signaling, was
indeed detected in CL6 cells exposed to DMSO, and BMP2
significantly down-regulated Wnt3a expression at day 3 (Fig. 4E).
By using the TOPflash plasmid [23] which includes the luciferase
gene driven by two sets of three copies of the TCF recognition site,
Wnt/b-catenin signaling was assessed to investigate the effect of
BMP2. Wnt/b-catenin signaling activity increased at 48 h after
treatment with DMSO. Activity was increased by DMSO
treatment but decreased by BMP2 (Fig. 4F). Time course analysis
revealed that Wnt/b-catenin activity peaked at 5 days after
DMSO treatment, and decreased thereafter (Fig. 4G). BMP2
inhibited DMSO-induced Wnt/b-catenin activity throughout the
experimental period (up to 14 days). These results imply that BMP
signaling inhibits CL6 cardiomyogenesis at the early stage through
inhibition of Wnt/b-catenin signaling.
Group Title Description GSM
20 Cord blood, primary UCB408E7-32 E7, hTERT, cord blood GSM210408
21 Fetal fibroblast, primary HFDPC cont. Normal follicular dermal papillar cell, primary GSM210409
PL112 Placenta, primary GSM210410
HF7-3 Fetal fibroblast, primary GSM210411
22 Bone marrow cell, primary 3F0664 Bone marrow cell (commercial item), primary GSM201145
BM-MSC Bone marrow-derived mesenchymal stem cells GSM38627
23 ES cell-derived mesenchymal cell H1 clone 2 ES cell-derived mesenchymal precursor GSM38628
H9 clone 1 ES cell-derived mesenchymal precursor GSM38629
24 Endometrial cell EPC100 E6, E7, hTERT, endometrial cell GSM210413
25 Bone marrow cell, primary Yub10F Bone marrow cell, primary GSM210414
26 Endometrial cell EPC hTERT+2 E6, E7, hTERT, endometrial cell GSM210415
EPC Control E6, E7, hTERT, endometrial cell GSM210416
27 Endometrial cell EPC214 E6, E7, hTERT, endometrial cell GSM210417
28 Menstruation blood-derived mesenchymal
cell, primary
#E4 Menstruation blood, primary GSM210418
#E4HRF Menstruation blood, HRF treatment, primary GSM210419
#E5HRF Menstruation blood, HRF treatment, primary GSM210420
29 Menstruation blood-derived mesenchymal
cell, primary
#E6 Menstruation blood, primary GSM210421
#E6HRF Menstruation blood, HRF treatment, primary GSM210422
30 Menstruation blood-derived mesenchymal
cell, primary
#E5 Menstruation blood, primary GSM210423
doi:10.1371/journal.pone.0002407.t001
Table 1. cont.
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PLoS ONE | www.plosone.org 4 June 2008 | Volume 3 | Issue 6 | e2407Figure 2. Grem1 enhanced cardiomyogenic differentiation in DMSO-induced CL6 cells. (A) Phase contrast micrograph of CL6 cells with
exposure to DMSO alone (a), Grem1 (125 ng/ml) and DMSO (b) for 14 days. The medium, including Grem1 and DMSO, was changed every day. CL6 cells
exhibited apparent spontaneous beating between days 9–11. Beating CL6 cell colonies are outlined by white lines. (B) Percentage of beating area in
differentiated CL6 cells. CL6 cell treated with Grem1 (125 ng/ml) and DMSO exhibited the strongest contraction. (C) RT-PCR analysis of the genes
encoding cardiac-specific transcriptional factors (Csx/Nkx2.5, Gata4, Mef2c, Hand2), circulating hormone (ANP, BNP), cardiac-specific proteins (MyLC-2a,
MyLC-2v, b-MyHC), cytokines (Bmp2, Bmp4, Fgf8, Grem1, Wnt1, Wnt3a, Wnt5a, Wnt7a, Wnt11), SM-MyHC,a n dGapdh (From top to bottom). Mouse total
heart RNA for the Csx/Nkx2.5, Gata4, Mef2c, Hand2, ANP, BNP, MyLC-2a, MyLC-2v, b-MyHC, Bmp2, Bmp4, Grem1, Wnt11, SM-MyHC,a n dGapdh genes, mouse
embryonic stem cell RNA for the Fgf8 gene, and mouse total skeletal muscle RNA for the Wnt1, Wnt3a, Wnt5a,a n dWnt7a genes were used for positive
controls. H2O (without RNA) served as a negative control. (D) Immunocytochemistry of CL6 cells 14 days after exposure to Grem1 (125 ng/ml) and DMSO
withMF20andcTnT(a),anda-actinin(b).CellnucleiarestainedwithDAPI.Clearstriationsareevident.(E)Immunocytochemistry of CL6 cells 14 days after
exposuretoGrem1 andDMSOwithcardiactroponinT (cTnT)andsarcomeric myosin (MF20). CL6cells treatedwithGrem1 (125 ng/ml)and DMSO(a),and
DMSO alone (b) stained positive for cTnT and MF20. Untreated CL6 cells, i.e. not exposed to Grem1(125 ng/ml) or DMSO, stained negative for cTnT and
MF20. Cell nuclei were stained with DAPI. (F) Percentage of MF20- and cTnT-double positive area.
doi:10.1371/journal.pone.0002407.g002
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Our bioinformatics study using the results from the global gene
expression analysis of human cells (GSM412342-41344 and
GSM201137-201145 at http://www.ncbi.nlm.nih.gov/geo) nom-
inated Grem1 as a candidate gene that may participate in
cardiomyogenesis. By using CL6 embryonic cells as a model of
cardiomyogenesis, we obtained two major findings: the first is that
Grem1 enhanced cardiomyogenic differentiation of DMSO-
induced CL6 cells at the early stage; the second is that Wnt/b-
catenin and BMP signaling activity had developmental stage-
specific effects on cardiomyogenesis (Fig. 5). Wnt/b-catenin
activity at the early stage enhanced embryonic cell differentiation
into cardiomyocytes, while suppressing this activity by BMP2 or
BMP4 proteins as reported in the avian embryo [26]. In contrast,
BMP signaling activity in the late stage enhanced cardiomyocytic
differentiation. Grem1 regulated the stage-specific Wnt/b-catenin
and BMP signaling activity on cardiomyogenesis.
Many studies have indicated that Grem1 is involved in cell
differentiation and development, such as osteogenesis [27], lung
morphogenesis [28], myogenesis [29], and limb formation [30],
through inhibition of BMP2 and BMP4. Grem1-null mice show
intact heart development, despite impairment of lung and kidney
[31], and therefore Grem1 is considered not to be involved in
cardiogenesis, or supplementary factors such as Noggin [32], with
a similar function, may compensate Grem1 during development.
Grem1 had an enhancing or promoting activity in in vitro
cardiomyogenesis, as is the case with platelet-derived growth
factor as a promoter of cell growth [33]. In this study, Grem1 was
involved in cardiomyocyte differentiation. However Grem1 alone
could not induce cardiomyocytic differentiation of CL6 cells in the
absence of DMSO (Fig. 2C and F), suggesting that Grem1 is solely
Figure 3. Percentage of myogenic differentiation by period of treatment with Grem1 in CL6 cells. (A) Protocol for treatment of Grem1
and DMSO. CL6 cells were passaged at 1.8610
5 cells in 6-well plate on Day 0. CL6 cells were exposed to Grem1 (125 ng/ml) and/or DMSO on the
indicated day. Day when the cells were exposed to the inducers is shown by ‘‘+’’ (in gray cells for clarity). The medium including Grem1 and DMSO
was changed every day. On day 14, the cells were immunocytochemically stained with MF20 antibody. (B) Myogenic differentiation of CL6 cells was
estimated by sarcomeric myosin (MF20)-positive area. CL6 cells were treated with Grem1 (125 ng/ml) and DMSO for the indicated days. (C) Myogenic
differentiation of CL6 cells was estimated by beating area. CL6 cells treated with DMSO and Grem1 (125 ng/ml) were incubated at indicated days.
doi:10.1371/journal.pone.0002407.g003
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PLoS ONE | www.plosone.org 6 June 2008 | Volume 3 | Issue 6 | e2407Figure 4. Cardiomyogenic differentiation in CL6 cells (days 1–3) is inhibited by BMP2. (A) RT-PCR analysis of the gene encoding
BrachyuryT, Tbx6, cardiac-specific transcriptional factor (Csx/Nkx2.5), cardiac-specific protein (b-MyHC), and Gapdh (From top to bottom) of CL6 cells
treated with DMSO alone, or DMSO and BMP2 (100 ng/ml) for the first 3 days (days 1–3). The medium, including BMP2 and DMSO, was changed every
day. (B) Percentage of MF20-positive area. Immunocytochemistry was carried out on CL6 cells 14 days after cells had been exposed to DMSO and
BMP2 (100 ng/ml) for the first 3 days (days 1–3). The asterisk indicates a significant statistical difference (P,0.05). (C) Quantitative real-time RT-PCR
analysis of the gene encoding Bmp2 (left), and Bmp4 (right) in CL6 cells treated with DMSO alone (open square), or DMSO and BMP2 (100 ng/ml)
(closed square) for the first 3 days (days 1–3). (D) BMP signaling activity of CL6 cells treated with DMSO alone (open square), or DMSO and BMP2
(100 ng/ml) (closed square) for the first 3 days (days 1–3) were determined by luciferase activity analysis using Id1 promoter-Lux (a firefly luciferase
reporter plasmid driven by the Id1 binding sites), pRL-CMV as co-transfected control, and Dual luciferase reporter assay system. Relative luciferase
unit of the CL6 cells untreated with inducers at day 3 is regarded as 0.1 (data not shown). (E) Quantitative real-time RT-PCR analysis of the gene
encoding Wnt3a in CL6 cells treated with DMSO alone (open square), or DMSO and BMP2 (100 ng/ml) (closed square) for the first 3 days (days 1–3).
(F) Wnt/b-catenin signaling activity of CL6 cells 48 h after exposure to DMSO, or DMSO and BMP2 (100 ng/ml) was determined by luciferase activity
analysis using TOPflash (a firefly luciferase reporter plasmid driven by two sets of three copies of the TCF binding site and herpes simple virus
thymidine kinase minimal promoter), pRL-CMV as co-transfected control, and Dual luciferase reporter assay system. Relative luciferase unit of the CL6
cells untreated with inducers is regarded as 0.1. The asterisk indicates a significant statistical difference (P,0.05). (G) Timeframe of Wnt/b-catenin
signaling activity in CL6 cells treated with DMSO alone (open square), or DMSO and BMP2 (100 ng/ml) (closed square) for the first 3 days (days 1–3).
Relative luciferase unit of the CL6 cells untreated with inducers at day 3 is regarded as 0.1 (data not shown).
doi:10.1371/journal.pone.0002407.g004
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mechanisms for Grem1-enhanced cardiomyogenesis at the early
stage is inhibition of the BMP signaling pathway [3]. Alternatively,
Grem1-enhanced cardiomyogenesis may be mediated through
proliferation of cardiac progenitor cells, as is the case of myogenic
progenitor proliferation by Grem1 [34], and this possibility is
supported by an increased number of sarcomeric myosin-positive
CL6 cardiomyocytes (Fig. 2E and F).
The stage specificity of the Grem1 effect is possibly correlated
with the biphasic and antagonistic effect of Wnt/b-catenin
signaling on cardiomyogenesis, depending on the stage of
development in vitro [25] and in vivo [35]. CL6 cells differentiated
into cardiomyocytes via mesodermal induction by the Wnt/b-
catenin signaling pathway at the early stage, and CL6 mesodermal
cells differentiated into cardiomyocytes induced by BMP2 at the
late stage. It is conceivable that embryonic cells, such as CL6 cells
and ES cells, differentiate into cardiomyocytes by inhibiting BMP
signaling via putative ‘‘mesodermal cells’’ or ‘‘cardiomyogenic
progenitors’’, or differentiation stages corresponding to these cells
(Fig. 5, Figure S2). The early stage process from embryonic cells to
mesodermal cells was mediated via Wnt/b-catenin signaling
(Fig. 4F, G), and was assessed by expression of BrachyuryT and
Tbx6 genes (Fig. 4A), which are target genes for Wnt/b-catenin
signaling [36]. BMP signaling antagonizes the cell fate-inducing
activity of Wnt/b-catenin [37]. When embryonic cells or
cardiomyogenic progenitors are induced to become mature
cardiomyocytes by cytokines and growth factors, we must be
careful with respect to the stage of cell differentiation because of
the biphasic differential action of the factors which are dependent
upon the differentiation stage.
In conclusion, we have demonstrated that Grem1 enhances the
commitment or determined path to cardiogenic differentiation of
CL6 teratocarcinoma cells. Apart from a role in development,
Grem1 may serve a clinical use in cardiology, like granulocyte
colony-stimulating factor that accelerates production of granulo-
cytes in both peripheral blood and bone marrow. Nomination of
Grem1 as a cardiomyogenic factor is based on hierarchical
clustering analysis using global gene expression data of human
cells. This bioinformatics approach may be useful for identifying
morphogens/factors that can induce differentiation of other cell
types/tissues/organs.
Materials and Methods
GeneChip analysis
GeneChip analysis was performed (Fig. 1A, Table 1) as
previously described [38]. Human genome-wide gene expression
was examined with the Human Genome U133A Probe array
(GeneChip; Affymetrix), which contains the oligonucleotide probe
set for approximately 23,000 full-length genes and expressed
sequence tags, according to the manufacturer’s protocol (Expres-
sion Analysis technical manual and GeneChip Small Sample
Target Labeling Assay version 2 technical note [http://www.
affymetrix.com/support/technical/index.affx]). Data analysis was
performed by the GeneChip Operation System (Affymetrix) and
GeneSpringGX software (Silicon Genetics). To normalize the
staining intensity variations between chips, the average difference
values for all genes on a given chip were divided by the median of
all measurements on that chip. Hierarchical-clustering analysis
was performed using a minimum distance value of 0.001, a
separation ratio of 0.5, and the standard definition of the
correlation distance.
Cell culture and differentiation
CL6 cells were grown on 100 mm dishes (Becton Dickinson) in
a-MEM (Gibco) supplemented with 10% fetal bovine serum (FBS)
(JRH Bioscience, Inc.), penicillin, and streptomycin, and were
maintained in a 5% CO2 atmosphere at 37uC. To induce
differentiation, CL6 cells were plated at a density of 1.8610
5 cells
in a 6-well plate (Becton Dickinson) or gelatin-coated 35 mm glass
base dishes (IWAKI) with a-MEM containing Grem1 (63 or
125 ng/ml: R&D system) and/or 1% dimethyl sulfoxide (DMSO)
for 14 days. Recombinant human bone morphogenetic protein-2
(BMP2) was purchased from R&D systems.
Reverse transcriptase-PCR (RT-PCR) and quantitative real-
time RT-PCR analysis
Total RNAs were extracted from differentiated and undiffer-
entiated CL6 cells and mouse embryonic stem (ES) cells with
RNeasy minikit and DNase I treatment (QIAGEN). Mouse ES cell
(129 strains) RNA, mouse heart total RNA (Clontech) and mouse
skeletal muscle/total RNA (UNITECH. Co., Ltd.) were used as a
positive control for each primer. Total RNA (2.0 mg each) for RT-
PCR was converted to cDNA with Superscript
TM III RNase H–
reverse transcriptase (Invitrogen), according to the manufacturer’s
manual. PCR conditions were optimized and linear amplification
range was determined for each primer by varying annealing
temperature and cycle number. PCR products were identified by
positive control size. RT-PCR was performed using the primers of
the genes of cardiac specific transcription factors: Csx/Nkx2.5,
Gata4, Mef2c, Hand2; circulating hormone: ANP, BNP; cardiac
structural proteins: b-MyHC, MyLC-2a, MyLC-2v; cytokines: Bmp2,
Bmp4, Fgf8, Grem1, Wnt1, Wnt3a, Wnt5a, Wnt7a, Wnt11; smooth
muscle structural protein: smooth muscle-myosin heavy chain
(SM-MyHC); the early mesodermal marker: BrachyuryT, T-box6
(Tbx6); and Gapdh as control. PCR was performed with exTaq
DNA polymerase and exTaq PCR buffer (TaKaRa) or LATaq
DNA polymerase and GC buffer I (TaKaRa) for 25 or 30 cycles,
with each cycle consisting of 95uC for 30 s, 50uC, 55uC, 60uCo r
65uC for 45 s, and 72uC for 45 s, with an additional 5 min
incubation at 72uC after completion of the final cycle. PCR
primers for the genes of Csx/Nkx2.5, Gata4, Mef2c, Hand2, ANP,
BNP, b-MyHC, MyLC-2a, MyLC-2v, Bmp2, Bmp4, Fgf8, Grem1,
Wnt1, Wnt3a, Wnt5a, Wnt7a, Wnt11, SM-MyHC, BrachyuryT, Tbx6,
and Gapdh (Table S1a) were obtained from Mouse Genome
Figure 5. Grem1-accelerated CL6 cardiomyogenesis through
regulation of BMP- and Wnt/b-catenin-signaling pathways. CL6
embryonic cells start to differentiate into mesodermal cells through Wnt/
b-catenin signaling pathway at the early stage (days 1–3), and
mesodermal CL6 cells differentiate into mature cardiomyocytes by BMP
pathway at the late stage (days 4–14). Grem1 accelerates DMSO-induced
cardiomyogenesis through inhibition of the BMP-signaling pathway.
doi:10.1371/journal.pone.0002407.g005
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were size-fractionated by 2% agarose gel electrophoresis.
Quantitative real-time RT-PCR was performed on an ABI
Prism 7700 Sequence Detection System (Applied Biosystems),
using 100 ng of cDNA in 25 ml reaction volume with 10 nmol/l of
each primer, and 12.5 ml SYBR Green Realtime PCR Master Mix
(TOYOBO). PCR primers for the genes of Bmp2, Bmp4, Wnt3a,
and Gapdh (Table S1b) were obtained from PrimerBank (http://
pga.mgh.harvard.edu/primerbank/index.html). Calculations were
automatically performed by ABI software (Applied BioSystems).
Immunocytochemistry
A laser confocal microscope (LSM510, Zeiss) was used for
immunocytochemical analysis. Differentiated and undifferentiated
CL6 cells were fixed with 4% paraformaldehyde (Wako) for 5 min
at 4uC and treated with 0.1% triton X-100 (Sigma) in PBS for
20 min at room temperature, then incubated for 20 min at room
temperature in a protein-blocking solution consisting of PBS
supplemented with 5% normal goat serum (DakoCytomation).
These CL6 cells were then incubated overnight with primary
antibody monoclonal anti-sarcomeric myosin antibody (MF20,
mouse IgG2b isotype, 1 mg/ml, University of Iowa Hybridoma
Bank) and Troponin T, and Cardiac Isoform Ab-1 clone 13-11
(cTnT, mouse IgG1 isotype, 1:300, Lab Vision Corp), or the
monoclonal anti-a-actinin (SARCOMERIC) CLONE EA-53 (a-
actinin, mouse IgG1 isotype, 1:300, Sigma) in PBS at 4uC. The
cells were extensively washed in PBS and incubated at room
temperature with Alexa Fluor 568-conjugated goat anti-Mouse
IgG2b (anti-MF20) (Molecular Probe; diluted 1:300), Alexa Fluor
488-conjugated goat anti-mouse IgG1 (anti-cTnT) (Molecular
Probe; diluted 1:300), Alexa Fluor 546-conjugated goat anti-
mouse IgG(H+L) (anti-a-actinin) (Molecular Probe; diluted 1:300),
and nuclei were counterstained with 49, 6-diamidino-2-phenylin-
dole (DAPI) (Wako; diluted 1:300) for 45 min. To prevent fading,
cells were then mounted in DakoCytomation Fluorescent
Mounting Medium (DakoCytomation).
Transfection and luciferase assays
Cells (8.0610
5) seeded and cultured in 60 mm dishes (Becton
Dickinson) were transfected 18 h after plating using Lipofectamine
2000 (Invitrogen) and PLUS reagent (Invitrogen) in Opti-MEM
(Gibco). Transfection contained 1.0 mg of TOPflash plasmid
(Upstate Biotechnology) for measurement of Wnt/b-catenin
activity, or 5.0 mg of the Id1 promoter-Lux plasmid (provided by
Dr Imamura and Dr Miyazono) for measurement of BMP-
induced Id1 gene transcription, and 0.5 mg of pRL-CMV
(Promega) as co-transfected control. Medium containing 10%
FBS was changed 3 h after transfection and transfected cells
(1.8610
5) were re-seeded in 6-well plates 24 h after transfection.
After 18 h, CL6 cells were induced with BMP2 (100 ng/ml) and
DMSO. CL6 cells were prepared for luciferase activity analysis
using Dual luciferase reporter assay system (Promega).
Area calculation
The regions of interest (beating area, immunostaining area)
were defined in Photoshop (Adobe systems) using the ‘magic wand’
tool. The total numbers of pixels identified were then counted
using the histogram function. At least five different fields were
measured for each dish.
Statistical analysis
Results, shown as the mean6SE, were compared by ANOVA
followed by Scheffe ´’s test, with P,0.05 considered significant.
Supporting Information
Figure S1 A semi-quantitative RT-PCR of cardiomyocyte-
specific genes. To investigate expression level of cardiomyocyte-
specific genes (Csx/Nkx2.5, Gata4, MyLC-2a, and MyLC-2v), a
semi-quantitative RT-PCR was performed from CL6 cells treated
with 1% DMSO and the indicated concentration of Grem1 for 14
days. Each RT-PCR product was electrophoresed in 2% agarose
gel, and was measured using ImageJ software (http://rsb.info.nih.
gov/ij/) to calculate the ratio of each gene to Gapdh. The
expression level for each gene is determined relative to that of
Gapdh, and expression level in CL6 cells treated with DMSO
alone was regarded as 1.0. The relative expression levels were
averaged from at least three independent experiments.
Found at: doi:10.1371/journal.pone.0002407.s001 (1.04 MB
DOC)
Figure S2 Grem1 enhanced cardiomyogenic differentiation of
mouse ES cells. Mouse ES cells (NCH1.5, C57BL/6J6129ter/Sv)
were cultured on a mouse embryonic fibroblast feeder layer
inactivated with 30 Gy c-irradiation in gelatin-coated 60 mm
dishes (Becton, Dickinson). Cells were grown in KnockOut
DMEM (Gibco) supplemented with 15% fetal bovine serum (Cell
Culture Technologies), 2 mM GlutaMAX (Gibco), 0.1 mM non-
essential amino acid (Gibco), 0.1 mM 2-mercaptoethanol (Gibco),
penicillin, streptomycin, and 2,000 U/ml mouse leukemia
inhibitory factor (LIF) (Chemicon). For cardiomyogenic differen-
tiation, ES cells were exposed to 125 ng/ml Grem1 (R&D systems)
for the three days. The cells were then trypsinized and cultured to
form embryonic bodies (EBs) from a single cell using a three-
dimensional culture system (without LIF) on low cell binding
dishes (96-well plate round bottom). This represented day 0 of EB
formation. On the next day, the medium was replaced with the
same medium without LIF. EBs were re-seeded on gelatin-coated
48-well plates with one EB per well, on day 8 after the start of EB
formation. The cardiomyogenic induction was estimated by the
beating EB number per total EB number, measured on day 12
under a phase-contrast microscope. Grem1 increased the
percentage of beating EBs to 69.2%, as compared with 26.7%
in EBs without Grem1 treatment. The numbers in parentheses
indicate the EB numbers counted.
Found at: doi:10.1371/journal.pone.0002407.s002 (1.27 MB
DOC)
Table S1 Primer sequences.
Found at: doi:10.1371/journal.pone.0002407.s003 (0.06 MB
DOC)
Movie S1 CL6 cells treated with DMSO alone. P19CL6 cells
are reproducibly and stably induced into beating cardiomyocytes
with DMSO.
Found at: doi:10.1371/journal.pone.0002407.s004 (1.66 MB
MOV)
Movie S2 CL6 cells treated with Grem1 (125 ng/ml) and
DMSO. Grem1 dramatically promotes DMSO-induced cardio-
myogenic differentiation of P19CL6 cells at a concentration of
125 ng/ml.
Found at: doi:10.1371/journal.pone.0002407.s005 (2.40 MB
MOV)
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